Anti-HER2 Treatment and Breast Cancer: State of the Art, Recent Patents, and New Strategies

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 4, Iss. 1, 2009-01 ,pp. : 9-18

Bentham Science Publishers

Access to resources Recommend Favorite

Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells

By Payne Kyle   Zoon Christine   Wan Wen   Marlar Khin   Keim Rebecca   Kenari Mehrab   Kazim A.   Bear Harry   Manjili Masoud  

Breast Cancer Research and Treatment, Vol. 142, Iss. 1, 2013-11 ,pp. : 45-57

Springer Publishing Company

Access to resources Recommend Favorite

Quantitative detection of HER2 protein concentration in breast cancer tissue does not increase the number of patients eligible for adjuvant HER2-targeted therapy

By                

Oncology Reports, Vol. 29, Iss. 4, 2013-01 ,pp. : 1475-1482

Spandidos Publications

Access to resources Recommend Favorite

Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 3, Iss. 3, 2008-11 ,pp. : 187-201

Bentham Science Publishers

Access to resources Recommend Favorite

Measurement of HER2 in Saliva of Women in Risk of Breast Cancer

By Abreu Pereira Denise  

Pathology & Oncology Research, Vol. 19, Iss. 3, 2013-07 ,pp. : 509-513

Springer Publishing Company

Access to resources Recommend Favorite